Jump to content
Wikipedia The Free Encyclopedia

Affymetrix

From Wikipedia, the free encyclopedia
American biotech company
"Affy" redirects here. For the confectionery, see Affy Tapple. For the school, see Affies.
This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
This article needs to be updated. Please help update this article to reflect recent events or newly available information. (March 2020)
A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (January 2015) (Learn how and when to remove this message)
This article needs additional citations for verification . Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Affymetrix" – news · newspapers · books · scholar · JSTOR
(March 2020) (Learn how and when to remove this message)
This article has an unclear citation style . The references used may be made clearer with a different or consistent style of citation and footnoting. (March 2020) (Learn how and when to remove this message)
(Learn how and when to remove this message)
Affymetrix, Inc.
Company typeSubsidiary
IndustryBiotechnology
Founded1992
HeadquartersSanta Clara, California, U.S.
Number of locations
11
Key people
Stephen Fodor, Frank Witney (CEO)
RevenueIncrease US$327 Million (FY 2009)[1]
Decrease US$-30.6 Million (FY 2009)[1]
Decrease US$-23.9 Million (FY 2009)[1]
Total assets Decrease US$612 Million (FY 2009)[2]
Total equity Decrease US$288 Million (FY 2009)[2]
Number of employees
1,141[3]
Parent Thermo Fisher Scientific
Websitehttps://www.thermofisher.com/us/en/home/life-science/microarray-analysis.html

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name.[4] The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.[5] [6]

In 1994, the company's first product under the "GeneChip" Affymetrix trademark, an HIV genotyping chip was introduced,[7] and the company went public in 1996.[8]

After incorporation, Affymetrix grew in part by acquiring technologies from other companies, including Genetic MicroSystems (slide-based Microarrays and scanners)[citation needed ] and Neomorphic (for bioinformatics) in 2000,[9] ParAllele Bioscience (custom SNP genotyping),[citation needed ] USB/Anatrace (biochemical reagents) in 2008,[10] Panomics (low to mid-plex applications) in 2008,[citation needed ] and eBioscience (flow cytometry) in 2012.[11] Affymetrix spun off Perlegen Sciences in 2000,[12] [13] as a discrete business focusing on wafer-scale genomics to characterize population-variance of genomic markers.[14]

In January 2014, the Food and Drug Administration approved Affymetrix's postnatal blood test, CytoScan Dx Assay, looking at whole-genome correlates of congenital abnormalities and other causes of childhood developmental delay.[15]

On January 8, 2016, Thermo Fisher Scientific announced its acquisition of Affymetrix for approximately 1ドル.3 billion,[16] which closed on March 31, 2016.[17]

History

[edit ]

Affymetrix, Inc. was spun-off from Affymax Research Institute by Alex Zaffaroni in 1993, and was eventually based in Santa Clara, California, United States.[18] It began as a unit in Affymax N.V. in 1991 under Fodor and his group.[18] [19] In the late 1980s, that group had developed methods for fabricating DNA microarrays, under the "GeneChip" Affymetrix trademark, using semiconductor manufacturing techniques.[citation needed ] The company's first product, an HIV genotyping GeneChip, was introduced in 1994[citation needed ] and the company went public in 1996.[20]

Acquisitions

[edit ]

Prior to its acquisition by Thermo Fisher, and its becoming a line of its products, Affymetrix, Inc. had acquired the technologies of a number of companies. It acquired Genetic MicroSystems for slide-based microarrays and scanners and Neomorphic for bioinformatics, both in 2000,[21] [22] ParAllele Bioscience for custom SNP genotyping,[when? ][citation needed ] USB/Anatrace for biochemical reagents in 2008,[verification needed ][23] eBioscience for flow cytometry in 2012,[verification needed ][24] and Panomics in 2008[verification needed ][25] and True Materials[when? ] to expand its offering of low to mid-plex applications.[26] [27] In 2000, Perlegen Sciences spun out from Affymetrix to focus on wafer-scale genomics for massive data creation and collection required for characterizing population variance of genomic markers and expression for the drug discovery process.[citation needed ]

FDA test approval

[edit ]

In January 2014, the Food and Drug Administration cleared a first-of-a-kind whole-genome postnatal blood test that can aid physicians in identifying the underlying genetic cause of developmental delay, intellectual disability, congenital anomalies, or dysmorphic features in children, where it was noted that "[a]bout 2 to 3 percent of U.S. children have some sort of intellectual disability, according to the National Institutes of Health."[28] The test, known as CytoScan Dx Assay, was designed to diagnose these disabilities earlier to expedite appropriate care and support.

References

[edit ]
  1. ^ a b c Affymetrix (AFFX) annual SEC income statement filing via Wikinvest
  2. ^ a b Affymetrix (AFFX) annual SEC balance sheet filing via Wikinvest
  3. ^ "Company Profile for Affymetrix Inc (AFFX)". Archived from the original on 2012年03月01日. Retrieved 2008年10月20日.
  4. ^ "Thermo Fisher Scientific to acquire Affymetrix". Grainews. Retrieved 2022年03月23日.
  5. ^ "Affymetrix and Illumina Settle Their Patent Disputes". fiercebiotech.com. 10 January 2008. Retrieved 2022年01月12日.
  6. ^ "Stephen Fodor, Jami Nachtsheim". genomeweb.com. 30 January 2015. Retrieved 2022年01月12日.
  7. ^ "Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics". biomerieux.com. Retrieved 2022年01月12日.
  8. ^ "AFFX Meaning AFFX Stock Meaning". acronym.io. Retrieved 2022年01月12日.
  9. ^ "Affymetrix to Acquire Neomorphic In a Deal Valued at 70ドル Million". Wall Street Journal. 2 October 2000. Retrieved 2022年01月14日.
  10. ^ "Affymetrix Sells Anatrace Unit to Investment Firm StoneCalibre". genomeweb.com. 15 October 2013. Retrieved 2022年01月28日.
  11. ^ "Affymetrix Completes eBioscience Acquisition". genomeweb.com. 26 June 2012. Retrieved 2022年02月02日.
  12. ^ "Perlegen Signs Its First Big Pharma Deal with GlaxoSmithKline, Finishes Fifty Genomes". genomeweb.com. 27 September 2002. Retrieved 2022年02月02日.
  13. ^ "National Library of Medicine" . Retrieved 2024年09月19日.
  14. ^ "A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies" (PDF). hivdb.stanford.edu. Retrieved 2022年02月09日.
  15. ^ "FDA OKs Postnatal Blood Test for Intellectual Disabilities". medscape.com. Retrieved 2022年02月09日.
  16. ^ Armental, Maria (8 January 2016). "Thermo Fisher Scientific to Buy Affymetrix in 1ドル.3 Billion Cash Deal". The Wall Street Journal . Retrieved 14 January 2016.
  17. ^ "Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by Affymetrix Stockholders". ir.thermofisher.com.
  18. ^ a b "Stephen P. A. Fodor (1953-)". DNA from the beginning. Archived from the original on March 5, 2016. Retrieved January 6, 2022.
  19. ^ "Affymetrix, Inc". Dun & Bradstreet. Archived from the original on January 6, 2022. Retrieved January 6, 2022.
  20. ^ "Affymetrix Inc: SEC CIK #0000913077". SEC Report. Retrieved January 6, 2022.
  21. ^ "Affymetrix Acquires Genetic MicroSystems". Bioresearch Online. 1999年09月14日. Retrieved 2009年03月12日.
  22. ^ "Affymetrix Announces Definitive Merger Agreement With Neomorphic, Inc". Affymetrix. October 2000. Archived from the original on 2013年01月16日. Retrieved 2009年03月12日.
  23. ^ "Affymetrix Acquisition of USB — Frequently Asked Questions" (PDF). Affymetrix. 2008年01月31日. Archived from the original (PDF) on 2011年07月17日. Retrieved 2009年03月12日.
  24. ^ "Affymetrix and eBioscience Amend Definitive Merger Agreement". Affymetrix. May 2012. Archived from the original on 2015年01月25日. Retrieved 2015年01月24日.
  25. ^ "Affymetrix to acquire Panomics" (PDF). Affymetrix. 2008年11月11日. Retrieved 2009年03月12日.
  26. ^ "Affymetrix and Singapore-based Start-up PathGEN Dx Sign Partnership for Diagnostic Test Development for Pathogen Detection". Reuters. 2012年08月24日. Archived from the original on 2015年09月24日.
  27. ^ "Singapore scientists develop chip that can identify 70,000 viruses". Archived from the original on 2014年01月03日. Retrieved 2013年05月28日.
  28. ^ Matthew Perrone (January 17, 2014). "FDA OKs Mental Disability Blood Test for Infants" – via Washington Times.
[edit ]
  • "Affymetrix—Corporate History". Affymetrix. Archived from the original on 2006年11月07日. Retrieved 2006年11月20日. Detailed, multi-document resource on the originating company's history, from its perspective, featuring a detailed timeline of acquisitions, photographs of early technology, etc.

AltStyle によって変換されたページ (->オリジナル) /